GLG News by Video Game Software and Hardware Experts (North America)

William GardnerPresident and Managing PartnerDigital Entertainment Insights, LLC

3D Impact on Video Gaming

August 19, 2010

Analysis of:Gaming Giants bet on 3D for next big boost | www.google.com

The advent of in-home capability for delivery of 3D content has begun to pave the way for the next generation of video game hardware manufacturers (SONY , Microsoft, Nintendo )and software publishers (EA - ERTS, ATVI, TTWO, etc.) to prepare for this next evolution of that entertainment form. DEI's David Ward has drafted a first look "white paper" on issues and opportunities that will become important.

William GardnerPresident and Managing PartnerDigital Entertainment Insights, LLC

Microsoft's X-Box Challenge

July 2, 2008

Analysis of:Microsoft reportedly to cut price of Xbox 360 to $299 | news.yahoo.com

There are several key implications from this price move. First of all, the X-Box 360 is not moving well at retail, and there is "push-back" from retail vendors to get the hardware moving again. This lack of movement is causing a slowdown  in software sales, forcing developers and publishers to reconsider longer term planning and will impact X-Box-360 sales even further. Lastly, the world wide demand for the Playstation 3 is on the rise, and Microsoft needs to stimulate the X-Box 360 space. One question, why now?

Frank FrystakPresidentFrystak Associates

Macys current performance

May 21, 2008

Analysis of:Macy's Same-Store Sales Down 2.6% | www.jckonline.com

Macys in store servicing of current customers is a key to there growth in this very tough retail climate. There addition of new branded merchandise catagoires , Ie Martha Stewart, Donald Trump , etc. gives them a creative edge to be competative in the next 2 qtrs. The jury is out for most better retailsers . Wal-Mart and Costco appear to be  weathering the economic storm as customers continue  to look for price driven value.

David RosenbergChief of Psychiatry and PsychologyCHILDREN'S HOSPITAL OF MICHIGAN

Neuronal nicotinic receptor agonists potential breakthrough for ADHD research

May 12, 2008

Analysis of:Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder | biz.yahoo.com

1. Effective treatment for ADHD 2. Well tolerated with few side effects 3. Help with smoking, a big problem in ADHD patients important 4. Advantage in not being Schedule II may be helpful

David RosenbergChief of Psychiatry and PsychologyCHILDREN'S HOSPITAL OF MICHIGAN

Important New Data for Children and Adolescents

May 12, 2008

Analysis of:FDA Approves Strattera® for Maintenance of ADHD in Children and Adolescents | newsroom.lilly.com

1. Important new finding given safety concerns raised about this and other treatmetns 2. Nice to have data back up what has long been done clinically 3. Stimulants still first line and lack of active comparator trial

David RosenbergChief of Psychiatry and PsychologyCHILDREN'S HOSPITAL OF MICHIGAN

Exciting new treatment for OCD and Social Anxiety Disorder

March 7, 2008

Analysis of:FDA Approves Luvox CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder and Obsessive Compulsive Disorder | pharmalive.com

1. Controlled release preparations are often better tolerated with fewer side effects than immediate release preparations 2. OCD and SAD are severe, highly prevalent and chronically disabling conditions 3. Despite presence of SSRIs and other treatment, e.g, cognitive behavioral therapy, up to 1/3 of patients with OCD or SAD do not respond to currently available treatments and among responders many do so only partially

David RosenbergChief of Psychiatry and PsychologyCHILDREN'S HOSPITAL OF MICHIGAN

FDA Approval of Abilify for Pediatric Bipolar disorder is a Major Advance

March 7, 2008

Analysis of:U.S. Food and Drug Administration Approves Abilify (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) | pharmalive.com

1. Despite common use of multiple psychotropic medications for bipolar disorder in youth, there are few FDA-approved treatments 2. Abilify is one of the safest and best tolerated of the atypical antipsychotics with fewer side effects than some of the other atypical antipsychotic medications 3. This treatment offers new hope to many children and their families

David RosenbergChief of Psychiatry and PsychologyCHILDREN'S HOSPITAL OF MICHIGAN

More questions raised than answers

February 5, 2008

Analysis of:Chantix And Suicide: The Latest Numbers | www.pharmalot.com

No good data that Chantix is associated with suicide Need more controlled research to answer questions Scary adverse events are not the same as side effects directly linked to medication

David RosenbergChief of Psychiatry and PsychologyCHILDREN'S HOSPITAL OF MICHIGAN

Pediatric Bipolar Disorder is an Urgent Public Health Problem

September 5, 2007

Analysis of:Bipolar Disorder Among Kids in U.S. Rising, Study Suggests | online.wsj.com

1. Pediatric bipolar disorder is an urgent public health problem 2. There is added recognition that this can occur in children 3. Very difficult to diagnose-need comprehensive assessment to ensure accurate diagnosis and as importantly not 'overdiagnosing'

David RosenbergChief of Psychiatry and PsychologyCHILDREN'S HOSPITAL OF MICHIGAN

BL-1020 the First Novel Antipsychotic in Quite a While

August 23, 2007

Analysis of:BIOLINERX STARTS PHASE II TRIAL OF BL-1020 FOR SCHIZOPHRENIA. | www.therapeuticsdaily.com

1. BL-1020 represents an important advance from Israel's top drug development company 2. Unique mechanism without Parkinsonian side effects or cardiovascular, metabolic, weight gain (from atypical antipsychotics 3. This may enhance treatment adherence with better outcomes 4. Likely will be useful for various other conditions, e.g, other psychoses, bipolar disorder, mood disorders, etc

Page : 12345Next1 to 10 of 43